Table 1.
Characteristics of Patients Enrolled in the GIHSN Study by Site in the 2018/2019 Influenza Season
| Recruiting Site | Laboratory Confirmed Influenza N (%Within Site) | Influenza Negative N (%Within Site) |
Age (Years) Median [IQR] |
Influenza Vaccine Uptake N (%Within Site)a |
|---|---|---|---|---|
| Overall | 3512 (21.9) | 12 510 (78.1) | 9.0 [1.1–61.0] | 2094 (13.1) |
| Northern Hemisphere | ||||
| France—Lyon | 43 (40.2) | 64 (59.8) | 71.0 [57.5–84.0] | 48 (44.9) |
| Spain—Valencia | 297 (9.8) | 2748 (90.2) | 73.0 [49.0–84.0] | 1220 (40.1) |
| Romania | 416 (44.5) | 518 (55.5) | 13.0 [2.5–53.0] | 100 (16.8) |
| Serbia | 336 (44.7) | 415 (55.3) | 60.0 [39.0–69.0] | 21 (2.8) |
| Russia-Moscow | 174 (21.2) | 648 (78.8) | 24.0 [2.3–52.0] | 29 (3.5) |
| Russia-St. Petersburg | 1096 (36.0) | 1945 (64.0) | 4.3 [1.6–22.0] | 127 (4.1) |
| Canada | 252 (53.8) | 216 (46.2) | 67.0 [52.0–79.0] | 203 (43.4) |
| Mexico | 163 (27.4) | 432 (72.6) | 4.5 [1.2–49.0] | 100 (16.8) |
| China-Shanghai | 164 (14.2) | 992 (85.8) | 0.8 [0.2–2.7] | 6 (0.5) |
| Lebanon | 124 (24.7) | 379 (75.3) | 37.0 [6.0–66.0] | 46 (9.1) |
| Intertropical Region | ||||
| India | 230 (23.5) | 748 (76.5) | 58.0 [38.0–70.0] | 15 (1.5) |
| Ivory Coast | 32 (7.8) | 377 (92.2) | 2.0 [0.7–28.0] | 17 (4.1) |
| Kenya | 22 (4.3) | 484 (95.7) | 1.2 [0.5–3.0] | 0 (0) |
| Colombia | 15 (12.2) | 108 (87.8) | 1.3 [0.4–28.0] | 27 (22) |
| Southern Hemisphere | ||||
| South Africa | 90 (5.6) | 1504 (94.4) | 0.7 [0.1–2.9] | 0 (0) |
| Brazil | 23 (6.2) | 346 (93.8) | 1.5 [0.4–5.0] | 149 (40.4) |
| Argentina | 18 (4.3) | 404 (95.7) | 1.0 [0.4–2.0] | 11 (2.6) |
| Peru | 17 (8.5) | 182 (91.5) | 3.2 [0.7–15.5] | 27 (13.6) |
Abbreviations: GIHSN, Global Influenza Hospital Surveillance Network; IQR, interquartile range.
NOTE: Influenza vaccine uptake by site is illustrated graphically in Supplementary Figure 1.
a
To calculate the influenza vaccine uptake, the entire enrolled hospitalized sample within the site was used as the denominator.